Relationship between antiretroviral drug plasma concentrations and viral load in children [1]

Journal of Acquired Immune Deficiency Syndromes

Volumn 32, Issue 1, 2003, Pages 112-115

  Treluyer, J M ^a   Burgard, M ^b   Cazali, N ^a   Quartier, P ^c   Veber, F ^c   Rey, E ^a   Alkaer, G ^c   Rouzioux, C ^b   Pons, G ^a   Blanche, S ^c  

^a Institut Cochin   (France)

^b HÔPITAL NECKER ENFANTS MALADES   (France)

^c ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; ANTIRETROVIRUS AGENT; DIDANOSINE; INDINAVIR; LAMIVUDINE; NELFINAVIR; NUCLEOSIDE ANALOG; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; STAVUDINE; ZALCITABINE; ZIDOVUDINE;

ADOLESCENT; ANTIVIRAL ACTIVITY; CHILD; DOSE CALCULATION; DRUG BLOOD LEVEL; DRUG MONITORING; DRUG TOLERABILITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LETTER; MAJOR CLINICAL STUDY; PATIENT COMPLIANCE; PEDIATRICS; PRIORITY JOURNAL; STANDARD; TREATMENT FAILURE; VIRUS LOAD;

EID: 0037234031     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/00126334-200301010-00016     Document Type: Letter

References (30)

1. Krogstad P, Wiznia A, Luzuriaga K, et al. Treatment of human immunodeficiency virus 1-infected infants and children with the protease inhibitor nelfinavir mesylate. Clin Infect Dis 1999;28:1109-18.
2. Cooper D, Clumeck N, Montaner J, et al. Analysis of HIV-1 clinical trials: statistical magic? Lancet 1999;353:2061-4.
3. Valdez H, Lederman MM, Woolley I, et al. Human immunodeficiency virus 1 protease inhibitors in clinical practice: predictors of virological outcome. Arch Intern Med 1999;159:1771-6.
4. Lucas GM, Chaisson RE, Moore RD. Highly active antiretroviral therapy in a large urban clinic: risk factors for virologic failure and adverse drug reactions. Ann Intern Med 1999;131:81-7.
5. Palumbo P. Antiretroviral therapy of HIV infection in children. Pediatr Clin North Am 2000;47:155-69.
6. Sadler BM, Gillotin C, Lou Y, et al. Pharmacokinetic and pharmacodynamic study of the human immunodeficiency virus protease inhibitor amprenavir after multiple oral dosing. Antimicrob Agents Chemother 2001;45:30-7.
7. Mueller BU, Zeichner SL, Kuznetsov VA, et al. Individual prognoses of long-term responses to antiretroviral treatment based on virological, immunological and pharmacological parameters measured during the first week under therapy. AIDS 1998;12:F191-6.
8. Hoetelmans RM, Reijers MH, Weverling GJ, et al. The effect of plasma drug concentrations on HIV-1 clearance rate during quadruple drug therapy. AIDS 1998;12:F111-5.
9. Burger DM, Hugen PW, Droste J, et al. Therapeutic drug monitoring of indinavir treatment-naïve patients improves therapeutic outcome after 1 year: results from ATHENA. The 2nd International Workshop on Clinical Pharmacology of HIV Therapy., Noordwijk, the Netherlands, April 2-4 2001, 2001.
10. Marzolini C, Telenti A, Decosterd LA, et al. Efavirenz plasma levels can predict treatment failure and central nervous system side effects in HIV-1-infected patients. AIDS 2001;15:71-5.
11. Fletcher CV, Acosta EP, Henry K, et al. Concentration-controlled zidovudine therapy. Clin Pharmacol Ther 1998;64:331-8.
12. Drusano GL, Yuen GJ, Lambert JS, et al. Relationship between dideoxyinosine exposure, CD4 counts, and p24 antigen levels in human immunodeficiency virus infection: a phase I trial. Ann Intern Med 1992;116:562-6.
13. Treluyer J, Rey E, Pons G. Pharmacokinetic principles in paediatric pharmacology: proof of differences beyond the neonatal period. In: Tindall B, ed. Paediatric pharmacology: toward evidence-based drug therapy. Vol. 6. London: Koren, G Diav-Citrin, O, 1998:399-418.
14. Burger DM, Hugen PW, Droste J, et al. Therapeutic drug monitoring of nelfinavir treatment-naïve patients improves therapeutic outcome after 1 year: results from ATHENA. The 2nd International Workshop on Clinical Pharmacology of HIV Therapy, Noordwijk, the Netherlands, April 2-4 2001, 2001.
15. Burger DM, Hoetelmans RMW, Hugen PWH, et al. Athena: a randomized, controlled clinical trial to evaluate whether therapeutic drug monitoring (TDM) contributes to reduced HIV-related morbidity and mortality. First International workshop on clinical pharmacology of HIV therapy. Noordwijk, the Netherlands, 30-31 March 2000, 2000.
16. Hoetelmans RM, Burger DM, Meenhorst PL, et al. Pharmacokinetic individualisation of zidovudine therapy: current state of pharmacokinetic-pharmacodynamic relationships. Clin Pharmacokinet 1996;30:314-27.
17. Hoetelmans RMW, vanHeeswijk RPG, Profijt M, et al. Comparison of the plasma pharmacokinetics and renal clearance of didanosine during once and twice daily dosing in HIV-1-infected individuals. AIDS 1998;12:F211-F216.
18. Kaul S, Christofalo B, Raymond RH, et al. Effect of food on the bioavailability of stavudine in subjects with human immunodeficiency virus infection. Antimicrob Agents Chemother 1998;42:2295-8.
19. Cato A, Qian J, Hsu A, et al. Multidose pharmacokinetics of ritonavir and zidovudine in human immunodeficiency virus-infected patients. Antimicrob Agents Chemother 1998;42:1788-93.
20. Holford NH. Target concentration intervention: beyond Y2K. Br J Clin Pharmacol 1999;48:9-13.
21. Morris RG. Target concentration strategy for cyclosporin monitoring. Clin Pharmacokinet 1997;32:175-9.
22. Watson DC, Farley JJ. Efficacy of and adherence to highly active antiretroviral therapy in children infected with human immunodeficiency virus type 1. Pediatr Infect Dis J 1999;18:682-9.
23. Mueller BU, Lewis LL, Yuen GJ, et al. Serum and cerebrospinal fluid pharmacokinetics of intravenous and oral lamivudine in human immunodeficiency virus-infected children. Antimicrob Agents Chemother 1998;42:3187-92.
24. Chadwick EG, Nazareno LA, Nieuwenhuis TJ, et al. Phase I evaluation of zalcitabine administered to human immunodeficiency virus-infected children. J Infect Dis 1995;172:1475-9.
25. Hughes W, McDowell JA, Shenep J, et al. Safety and single-dose pharmacokinetics of abacavir (1592U89) in human immunodeficiency virus type 1-infected children. Antimicrob Agents Chemother 1999;43:609-15.
26. Kline MW, Dunkle LM, Church JA, et al. A phase I/II evaluation of stavudine (d4T) in children with human immunodeficiency virus infection. Pediatrics 1995;96:247-52.
27. Lewis LL, Venzon D, Church J, et al. Lamivudine in children with human immunodeficiency virus infection: a phase I/lI study. The National Cancer Institute Pediatric Branch-Human Immunodeficiency Virus Working Group. J Infect Dis 1996;174:16-25.
28. Luzuriaga K, Bryson Y, McSherry G, et al. Pharmacokinetics, safety, and activity of nevirapine in human immunodeficiency virus type 1-infected children. J Infect Dis 1996;174:713-21.
29. Bardsley-Elliot A, Plosker GL. Nelfinavir: an update on its use in HIV infection. Drugs 2000;59:581-620.
30. Baede-van Dijk PA, Hugen PW, Verweij-van Wissen CP, et al. Analysis of variation in plasma concentrations of nelfinavir and its active metabolite M8 in HIV-positive patients. AIDS 2001;15:991-8.